HWHG(SH:600079) Xin Lang Cai Jing·2026-01-12 08:15Core Viewpoint - ST Renfu's subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has received the approval notice from the National Medical Products Administration for the drug registration application of Buprenorphine Hydrochloride Injection, indicating a significant step in expanding its product portfolio in the analgesic market [1] Group 1 - The approved indication for Buprenorphine Hydrochloride Injection includes its use as an analgesic during anesthesia induction and postoperative pain management [1] - Yichang Renfu obtained clinical trial approval for the use of Buprenorphine Hydrochloride Injection in ICU pain management in September 2022, classified as a chemical drug of category 2.4 [1] - The total R&D investment in this project has reached approximately 16 million RMB [1]